A Prospective International Multicenter Phase II Study to Evaluate the Efficacy, Safety and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Previous Therapy With Checkpoint Inhibitor Treatment
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2017
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms IO-PAZ
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 17 Nov 2017 Planned End Date changed from 2 Nov 2020 to 16 Dec 2020.
- 17 Nov 2017 Planned primary completion date changed from 2 Nov 2020 to 16 Dec 2020.
- 17 Nov 2017 Status changed from not yet recruiting to recruiting.